Clinical trials: sponsored by Sir Run Run Shaw Hospital
Surgical Bleeding, Hemorrhage
A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)
This is a multicenter, randomized, single-blind, positive-controlled, non-inferiority clinical trial. The purpose is to evaluate the safety and effectiveness of the absorbable multilayer fibrillar regenerated oxidized cellulose…
- Conditions
- Surgical Bleeding, Hemorrhage, Oxidized Regenerated Cellulose
- Trial name
- ZXS2022 (NCT07764055)
- Testing
- Absorbable Multilayer Fibrillar Regenerated Oxidized Cellulose, SURGICEL Absorbable Hemostat (Absorbable Hemostatic Gauze)
- Where
- 6 sites in China
- Volunteers
- 288 people
- Sponsor
- Medprin Regenerative Medical Technologies Co., Ltd.
Advanced Solid Tumor, Tumor Infiltrating Lymphocytes
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v.
- Conditions
- Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05087745
- Testing
- Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Gastric or Gastroesophageal Junction Cancer
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer patients, to…
- Trial name
- NCT04053205
- Testing
- Gentuximab, Paclitaxel
- Where
- 12 sites in China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study.
- Trial name
- MUST Ⅱ (NCT07153744)
- Testing
- Aspirin, Shexiang Baoxin Pill
- Where
- China
- Volunteers
- 9,588 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Arrhythmias, Cardiac, Paroxysmal Atrial Fibrillation
InsightPFA Trial of the LotosPFA Catheter
This trial aims to determine whether the InsightPFA for PVI is as effective and safe as standard RFA in the treatment of symptomatic paroxysmal AF.
- Trial name
- InsightPFA (NCT06014996)
- Testing
- Pulsed Field Ablation (PFA) Therapy, Radiofrequency Ablation（RAF）Therapy
- Where
- 10 sites in China
- Volunteers
- 292 people
- Sponsor
- Insight Medtech Co., Ltd.
Coronary Artery Disease, Heart Diseases
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Coronary angiography-derived FFR assessment (AngioQFA) is a novel technique for physiological lesion assessment based on 3-dimensional (3D) quantitative coronary angiography (QCA) and virtual hyperemic flow derived from contrast…
- Conditions
- Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT06039748
- Testing
- AngioQFA
- Where
- 5 sites in China
- Volunteers
- 330 people
- Sponsor
- Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Advanced Colorectal Cancer
A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer
This is a multicenter, randomized, open-label, two-stage Phase IIb clinical study to evaluate the efficacy and safety of B1962 in the treatment of advanced colorectal cancer.
- Trial name
- NCT06838546
- Testing
- B1962
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Coronary Artery Disease, Coronary Disease
Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for Physiological Measurements
TruePhysio pressure microcatheter is a novel device for evaluating the functional significance of coronary stenosis, and its safety and efficacy on the measurement of hyperemic index have been validated in the previous SUPREME…
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia
- Trial name
- SUPREME II (NCT05417763)
- Testing
- Randomized physiological measurements by the two systems
- Where
- 11 sites in China
- Volunteers
- 487 people
- Sponsor
- Insight Lifetech Co., Ltd.
Upper Tract Urothelial Carcinoma
Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection
Clinical trial to determine the efficacy (sensitivity and specificity) of Anchordx's urine DNA methylation/somatic mutation assay for detecting upper tract urothelial carcinoma compared to pathology in patients.
- Trial name
- NCT04948528
- Testing
- Active Comparator: Surgery Pathology or Cystoscopy, Active Comparator: Clinical Diagnosis
- Where
- China
- Volunteers
- 490 people
- Sponsor
- AnchorDx Medical Co., Ltd.
Advanced Solid Tumor
Study of LM-102 in Patients With Advance Solid Tumors
This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2).
- Trial name
- NCT05008445
- Testing
- LM-102 Injection, LM-102 Injection combined with SOC
- Where
- China
- Volunteers
- 11 people
- Sponsor
- LaNova Medicines Development Co., Ltd.
Multiple Myeloma
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors).
- Trial name
- NCT04650724
- Testing
- T cell infusion agent targeting BCMA chimeric antigen receptor
- Where
- China
- Volunteers
- 3 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.